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Abstract 
The emergence of bone as an endocrine regulator has prompted a re-evaluation of the role of 
bone mineralization factors in the development of metabolic disease. Ectonucleotide 
pyrophosphatase/phosphodiesterase-1 (NPP1) controls bone mineralization through the 
generation of pyrophosphate and is elevated in dermal fibroblast cultures and muscle of 
patients with insulin resistance. We investigated the metabolic phenotype associated with 
impaired bone metabolism in mice lacking the NPP1 gene (Enpp1-/- mice). Enpp1-/- mice 
exhibited mildly improved glucose homeostasis on a normal diet but showed a pronounced 
resistance to obesity and insulin resistance in response to chronic high fat feeding. Enpp1-/- 
mice had increased levels of the insulin sensitising bone-derived hormone osteocalcin but 
unchanged insulin signaling within osteoblasts. A fuller understanding of the pathways of 
NPP1 may inform the development of novel therapeutic strategies for treating insulin 
resistance. 
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Introduction 
 
Bone remodelling is a highly conserved and regulated process that controls bone homeostasis 
and maintains skeletal structural integrity. This vital function is characterized by alternating 
phases of bone resorption by osteoclasts and bone formation by osteoblasts, and has a high 
energetic cost (Ducy et al., 2000). More recently it was proposed that insulin signaling 
mediates communication between bone remodelling and metabolic control (Fulzele et al., 
2007; Lee et al., 2007; Ferron et al., 2010).  Osteocalcin, a secreted protein that is specifically 
expressed in osteoblasts, is essential for this function of the skeleton. Hormonally active 
osteocalcin (in an under- or un-carboxylated form) acts to increase β-cell proliferation, 
insulin secretion, peripheral insulin sensitivity and energy expenditure (Ferron et al., 2008; 
Fulzele et al., 2010). This raises the possibility that other factors controlling bone remodelling 
impact upon metabolic homeostasis. 
 
Ectonucleotide pyrophosphatase/phosphodiesterase-1 (NPP1), also known as plasma cell 
membrane glycoprotein 1 (PC-1), is the founding member of the NPP family, consisting of 
seven isozymes with a structurally related catalytic domain. The NPPs hydrolyze 
phosphodiester or pyrophosphate bonds in various substrates, including nucleoside 
triphosphates, lysophospholipids, and choline phosphate esters (Bollen et al., 2000; Stefan et 
al., 2000; Zimmermann et al., 2012).  NPP1 is a glycoprotein that forms disulphide-bonded 
homodimers in the plasma membrane and mineral-depositing matrix vesicles of osteoblasts 
and chondrocytes (Hessle et al., 2002; Johnson et al., 2001; Terkeltaub et al., 2006; 
Vaingankar et al., 2004). NPP1 hydrolyzes extracellular nucleotides into inorganic 
pyrophosphate (PPi), a potent inhibitor of hydroxyapatite (HA) crystal formation in 
mineralization-competent tissues (Terkeltaub et al., 2001). Mice lacking NPP1 (Enpp1-/-) 
have severe mineralization defects, which are associated with abnormally low PPi levels 
(Anderson et al., 2005; Johnson et al., 2003; Sali et al., 1999). Phenotypic features of Enpp1-/- 
mice include significant alterations in the mineralization of long bones and calvaria, and 
pathologic perispinal soft tissue and medial arterial calcification (Mackenzie et al., 2012a; 
Mackenzie et al., 2012b; Sali et al., 1999).  
 
Impaired insulin action (insulin resistance) is a significant risk factor for type 2 diabetes 
(DeFronzo, 1988). NPP1 negatively modulates insulin receptor signaling and has been 
proposed as a pathogenic factor predisposing to insulin resistance (Goldfine et al., 2008; 
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Prudente et al., 2009). ENPP1 is overexpressed in skeletal muscle, adipose tissue, fibroblasts 
and lymphocytes of insulin-resistant individuals (Frittitta et al., 1997; Frittitta et al., 1998; 
Goldfine et al., 2008; Stentz et al., 2007; Teno et al., 1999).  Additionally, overexpression of 
NPP1 in cultured cells inhibits insulin receptor autophosphorylation and downstream 
signaling (Grupe et al., 1995). Further studies have shown that NPP1 binds to insulin receptor 
and inhibits the insulin-induced conformational changes that lead to insulin receptor 
autophosphorylation and tyrosine kinase activation (Maddux et al., 1995; Maddux et al., 
2000). Studies on the NPP1 Lys121Gln (K121Q) polymorphism (Pizzuti et al., 1999) a 
putative genetic determinant of human insulin resistance, led further support to NPP1 having 
a role in the etiology of human insulin resistance. In vitro studies have provided evidence for 
the increased susceptibility to insulin resistance of the Gln121 variant (Di Paola et al., 2011), 
with a Lys121Gln meta-analysis conducted on a European population showing a modest 
increase of the Gln allele in those at risk of type 2 diabetes (McAteer et al., 2008).  
 
Despite the recognized importance of NPP1 in the control of bone mineralization, its 
contribution to the regulation of glucose metabolism is less clear. Given that elevated NPP1 
is associated with insulin resistance (Goldfine et al., 2008; Prudente et al., 2009), we 
hypothesized that NPP1 gene deletion would promote improved glucose homeostasis in the 
context of obesity-associated diabetes. To test this we challenged Enpp1-/- mice with chronic 
exposure to a high fat diet. 
 
Results 
 
Enpp1-/- mice show unaltered fat mass on control diet  
There was no significant difference in body weight gain from 4 weeks of age between WT 
and Enpp1-/- mice (Fig. 1A), yet a significant reduction in quadratus femoris muscle mass 
was observed from 4 weeks of age in Enpp1-/- mice (12%; P<0.05; Fig. 1B) with no 
differences in soleus muscle (Fig. 1C). The loss of muscle mass in the quadratus femoris, a 
key target of exercise loading, is a likely consequence of the debilitating arthritis that the 
Enpp1-/- mice exhibit (Filippin et al., 2013). No effect of genotype on food intake was noted. 
To assess onset and severity of arthritis, stride length was assessed using walking gait 
analysis. From 6 weeks of age, the stride length of the Enpp1-/- mice was significantly 
reduced (P<0.05), as was the progressive increase in stride length with advancing age (Fig. 
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1D). No differences in mRNA expression of muscle genes such as Mstn, Fbxo32 or Fndc5 
were noted in these muscles (data not shown). 
 
There were no differences in white (gonadal, subcutaneous and mesenteric) or brown fat 
mass (Fig. 1E) and no changes in mRNA levels of key genes for adipogenesis (Pparg), 
lipolysis (Prkaa20), mitochondrial metabolism (Cpt1a) or glucose transport (Slc2a4) in 
gonadal or brown fat mass (data not shown). However, Cpt1a and Slc2a4 mRNA expression 
in the subcutaneous fat mass was significantly reduced in Enpp1-/- mice (50%; P<0.05; Fig. 
1F).  
 
Chronic deficiency of NPP1 in mice induces insulin sensitization on control diet. 
Due to the recognized inhibitory activity of NPP1 on the insulin receptor (Maddux et al., 
2000), we tested whether global deletion of Enpp1 would translate into changes in whole 
body glucose metabolism. Adult Enpp1-/- mice showed normal glucose tolerance tests (GTT) 
(Fig. 2A,D) but with a lower glucose-stimulated insulin secretion (GSIS) peak across the 
GTT indicating insulin sensitization (Fig. 2B,D). Adult Enpp1-/- mice also showed normal 
insulin tolerance tests (ITT) (Fig. 2C,D) and there were no differences in insulin secreting 
islet size or number in the pancreas of Enpp1-/- mice (Fig. 4 E, F). 
 
Enpp1-/- mice show obesity-resistance and improved insulin tolerance in response to 
chronic high fat diet challenge. 
Enpp1-/- mice showed resistance to weight gain caused by chronic high fat feeding compared 
to WT mice (Fig. 3A,B). Of note, quadratus femoris mass increased with HF diet in the 
Enpp1-/- mice (40% increase compared to control diet; P<0.05), whereas walking gait, as 
denoted by stride length, remained significantly reduced (P<0.05) (Fig. 3C). 
 
Enpp1-/- mice showed reduced white adipose tissue (WAT) mass (P<0.01; Fig. 3D) and 
adipocyte cell diameter (Fig 3E). Conversely, a marked increase in brown fat mass (37%; 
P<0.001; Fig. 3F) was noted. The gonadal fat pad showed a significant increase in PGC1α 
and Fndc5 (Fig. 3H), which are indicative of increased mitochondrial biogenesis. However 
there was no change in Ucp1 mRNA levels (Fig. 3H) and hence no evidence for increased 
canonical thermogenesis or white fat browning as a mechanism underlying the reduced 
adiposity and improved metabolic profiles.  In WAT, expression of white fat markers (e.g. 
Cpt1; Prkaa2) remained unaltered with HF diet (Fig. 3G-H). Moreover, micro-vesicular fat in 
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the liver, as detected by oil red O staining, was notably reduced in Enpp1-/- mice in 
comparison to WT littermates (Fig. 3I). No gross effect of high fat diet challenge was seen on 
kidney, brain, cardiovascular or muscle tissue architecture in either genotype. 
 
Glucose tolerance was comparable between genotypes (Fig. 4A,D). However, the insulin 
level (GSIS) across the GTT was lower in Enpp1-/- mice, indicating potential insulin 
sensitization (Fig. 4B,D). Improved Enpp1-/- insulin sensitivity was confirmed by an insulin 
tolerance test (Fig. 4C,D). Compared to wild type control mice, no significant differences in 
insulin secreting islet size or number in the pancreas of Enpp1-/- mice were observed (Fig. 4 
E, F). 
 
Do osteoblasts regulate insulin sensitivity in the Enpp1-/- mice? 
Given that NPP1 is a negative regulator of insulin signaling, we investigated whether 
osteoblast insulin signaling might link NPP1 deficiency and improved whole glucose 
homeostasis. Initially, we considered the distribution (Fig. 5A) and mRNA expression (Fig 
5B) of the insulin receptor in confluent monolayers of primary calvarial osteoblasts, with no 
effect of genotype observed. Furthermore there was no effect of NPP1 deletion on insulin-
stimulated Akt, Erk1/2 or GSK3β phosphorylation between Enpp1-/- and WT primary 
calvarial osteoblasts cultured in vitro (Fig. 5C). However, at 12 weeks of age Enpp1-/- mice 
exhibited increased concentrations of the osteoblast-derived insulin sensitizing hormone 
undercarboxylated (GLU13) (119%, P<0.05; Fig. 5D) and uncarboxylated (GLU) (156%, 
P<0.05; Fig. 5E) osteocalcin, while carboxylated (GLA13) and total osteocalcin levels were 
comparable to WT (Fig. 5F,G). Additionally, the degree of osteoblast and osteoclast activity 
was assessed by ELISA analysis of serum from Enpp1-/- and WT mice. No changes in the 
bone formation marker P1NP were noted (Fig. 5H), whereas a significant increase in the bone 
resorption marker CTx was observed in Enpp1-/- mice compared to WT controls (P<0.05; Fig. 
5I). Together these data suggest that the increase in undercarboxylated osteocalcin detected in 
Enpp1-/- mice as a result of increased bone resorption may induce the altered insulin 
sensitivity phenotype observed.  
 
Chronic high fat diet challenge induces brittle bone formation in WT mice and 
exacerbates the bone phenotype of Enpp1-/- mice. 
Given the detrimental effects of obesity on bone (Leslie et al., 2012), we next considered the 
effects of chronic high fat challenge on the bone physiology of the Enpp1-/- mouse.  
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Following a chronic high fat diet challenge, trabecular bone in WT mice showed a 
significantly altered microarchitecture resulting in thinner and more disorganized trabeculi, 
compared with mice reared on a control diet (Table 1). Cortical bone in WT mice fed a high 
fat diet showed a significantly increased bone mineral density compared with mice reared on 
a control diet (BMD; P<0.01). However, cortical thickness was unchanged by the high fat 
diet resulting in a more brittle bone as determined by the significantly decreased work to 
fracture (P<0.05) and post-failure work (P<0.05) observed in the three point bending analysis 
(Table 1). 
 
Enpp1-/- mice displayed a significant deterioration of the already compromised trabecular 
architecture following a chronic high fat diet challenge, as exemplified by the significant loss 
of connectivity indicated by the trabecular pattern factor, the loss of trabecular bone as 
measured by percentage of bone volume (BV/TV) and the reduced trabecular organization 
when compared to control diet mice (Table 1 and Fig. 6A-D). The tibiae of Enpp1-/- mice 
displayed a significantly reduced cortical thickness (10%; P<0.01). This also translated into a 
weaker, more brittle bone as measured by three point bending parameters whereby the work 
to fracture and post-failure was significantly reduced by 34% and 50% respectively (P<0.05; 
Table 1).  A high fat diet challenge also induced a significant decrease in bone modelling in 
Enpp1-/- mice, as indicated by the significant reduction in P1NP as a marker of bone 
formation (38%; P<0.001; Fig. 6E) and CTX as a marker of bone resorption (20%; P<0.001; 
Fig. 6F). These unique data highlight that a chronic high fat challenge has critical effects on 
the severity of the Enpp1-/- bone phenotype. 
 
Discussion 
 
The role of NPP1 in controlling the pace of bone mineralization has been firmly established 
through the study of in vivo mouse models. This enzyme is crucial for the regulation of bone 
mineralization through the generation of PPi from nucleotide precursors. Enpp1-/- mice 
display a distinct phenotype, including altered long bone and calvarial mineralization, and 
pathologic soft tissue calcification (Mackenzie et al., 2012a; Mackenzie et al., 2012b; Sali et 
al., 1999).  The necessity of NPP1 for physiological skeletal mineralization combined with 
the considerable evidence linking NPP1 expression with insulin resistance (Bacci et al., 2007; 
Baratta etal., 2008; Chandalia et al., 2012; González-Sánchez et al., 2008; Harmey et al., 
7 
 
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
Ac
ce
pt
ed
 m
an
us
cr
ip
t
2004), led us to investigate whether NPP1 has a functional role in bone as a novel regulator 
of energy metabolism.  
 
In the present study we have examined the full impact of chronic suppression of NPP1 and 
provide new evidence demonstrating that ablation of the bone mineralization inhibitor NPP1 
protects against insulin resistance, obesity and diabetes. Enpp1-/- mice exhibited insulin 
sensitization, and in response to a chronic high fat diet challenge displayed improved insulin 
tolerance and pronounced obesity-resistance. These novel data extend recent in vitro studies 
where the suppression of NPP1 expression in liver, skeletal muscle and pancreatic beta-cells 
improved insulin sensitivity (Di Paola et al., 2011). The observation of enhanced insulin 
sensitivity following adenoviral knockdown of liver NPP1 expression in a mouse model of 
diabetes (db/db) (Lepr-/-) further supports our findings (Zhou et al., 2009). In comparison 
with db/db mice treated with a control virus, db/db mice treated with the Enpp1shRNA 
adenovirus had 80% lower hepatic Enpp1 mRNA levels, 25% lower fasting plasma glucose 
and significantly improved glucose tolerance. This critical paper (Zhou et al., 2009) 
highlights the bone independent effects of NPP1, and together with our findings, supports the 
proposition that NPP1 inhibition is a potential therapeutic approach for the treatment of type 
2 diabetes.   
 
The present study provides the first demonstration of an association between osteocalcin 
carboxylation status and NPP1. Enpp1-/- mice presented with increased levels of 
undercarboxylated osteocalcin and the bone resorption marker CTX. These data support 
recent findings indicating that insulin signaling in osteoblasts favors bone resorption by 
osteoclasts, with decarboxylation of osteocalcin occurring in resorption lacunae, resulting in 
increased circulating undercarboxylated osteocalcin and a positive feedback loop on insulin 
secretion (Ferron et al., 2010; Lacombe et al., 2013). However, our studies undertaken in 
calvarial osteoblast cultures did not reveal a role for NPP1 as a modulator of insulin signaling 
in osteoblasts in vitro, suggesting that this model may not fully reflect osteoblast activity in 
vivo. Further studies involving the specific knockout of the insulin receptor in Enpp1-/- 
osteoblasts are therefore required to categorically confirm these data. Given the recent 
important observation that osteoclasts regulate energy metabolism (Lacombe et al., 2013), it 
is also vital to determine whether Enpp1-/- osteoclasts show any functional defects.  
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The distinct phenotype of the Enpp1-/- mouse may also directly influence the metabolic 
parameters observed in the present study. Enpp1-/- mice showed reduced body weight, 
decreased stride length and significant muscle reduction. These data are highly compatible 
with the observed osteoarthritic phenotype (Mackenzie et al., 2012a; Sali et al., 1999), which 
may modulate the insulin sensitization induced by NPP1 loss. Indeed, metabolic osteoarthritis 
(OA) has now been characterized as a subtype of OA, and has been highlighted as a new 
facet of the definition of Metabolic Syndrome, supported by its strong associations and 
shared mechanisms with other Metabolic Syndrome components (Zhuo et al., 2012). Further 
research, however, is needed to define the reciprocal influence of OA on the currently 
accepted components of Metabolic Syndrome, and the putative role of NPP1. 
 
The insulin sensitized phenotype observed in the Enpp1-/- mice may be a direct consequence 
of NPP1 ablation in insulin sensitive tissues such as liver, adipose and skeletal muscle. 
Overexpression of NPP1 in liver and muscle induces insulin resistance and hyperglycemia 
(Maddux et al., 2006). Moreover, overexpression of NPP1 in adipocytes leads to adipose 
insulin resistance, reduction in fat cell lipid storage and systemic insulin resistance and 
glucose intolerance akin to the effects of lipodystrophy (Pan et al., 2011). Our data support a 
beneficial effect of NPP1 deficiency being manifested potentially through improved insulin 
sensitivity in liver, muscle and adipose. However, one key difference in the Enpp1-/- mice is 
that insulin sensitization is associated with pronounced reduction in adipose tissue lipid 
storage without ectopic lipid accumulation in other organs. This suggests an overarching 
beneficial effect of Enpp1 deficiency on energy expenditure that likely involves other tissues. 
This may include increased muscle mitochondrial biogenesis through PGC1-α, a key 
regulator of energy metabolism (Ferron et al., 2012) or effects of increased bone turnover. 
Tissue specific ablation of NPP1 is therefore required in future work to pinpoint the 
individual tissue(s) driving the metabolic phenotype of the Enpp1-/- mouse. Furthermore, the 
association of the NPP1 K121Q polymorphism with insulin resistance in several human 
populations (Baratta et al., 2008; Stolerman et al., 2008) highlights the need for further 
studies specifically investigating the impact of this variant of NPP1 on metabolism. One of 
the premises of targeting NPP1 as treatment to type 2 diabetes-induced insulin resistance is 
that the inhibition of insulin receptor and NPP1 interactions happens independently of its 
pyrophophosphatase/phosphodiesterase activity, although the exact mechanism is still 
unknown (Chin et al., 2009).  
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Obesity is linked to normal or higher BMD accompanied by a paradoxical increase in fracture 
risk (Leslie et al., 2012). Our studies mimic this clinical setting of an obesity-induced bone 
phenotype in the WT mouse, where the bone is more brittle despite a higher BMD.  
Furthermore, our data show that a HFD challenge induces a decrease in bone modelling 
which results in an enhanced deterioration of bone architecture and mechanical properties, 
which are even more pronounced in the Enpp1-/- mice. This latter observation may reflect the 
abnormally low levels extracellular PPi observed in these mice, which would result in 
insufficient PPi substrate for TNAP to generate Pi for normal mineral formation, as 
previously discussed (Anderson et al., 2005). Furthermore, an accumulation of nucleotide 
triphosphates due to lack of hydrolysis by NPP1 (Prosdocimo et al., 2009) may have a 
downstream effect on bone remodelling through purinergic signaling (Orriss et al., 2011). No 
differences in cortical porosity were seen between either genotype or diet, however it was not 
possible to distinguish between vascularity, osteocyte lacunae and areas of non-mineralized 
matrix at the resolution examined. Further investigations specifically examining these 
individual components using nanoCT would therefore be of great interest. 
 
In conclusion, our data adds to the body of evidence (Goldfine et al., 2008; Prudente et al., 
2009) supporting NPP1 deficiency as protective against insulin resistance. We demonstrate 
for the first time that ablation of NPP1 alters osteocalcin carboxylation status, whilst 
protecting against obesity and diabetes (Fig. 7). A fuller understanding of the pathways of 
NPP1 may inform the development of novel therapeutic strategies for treating insulin 
resistance. 
 
Materials and Methods 
 
Animal model 
The generation and characterization of germline Enpp1-/- mice have been reported previously 
(Mackenzie et al., 2012a; Sali et al., 1999). Heterozygote breeders were used to generate 
distinct litters. Offspring carrying the mutant Enpp1 gene were identified by PCR and 
performed by performed by Genetyper (Genetyper, New York,USA). Male mice were fed a 
high fat diet (HFD, 58% fat, DBM Scotland, Broxburn, UK) or control diet (6.2% fat, Harlan 
Laboratories, Indianapolis, IN, USA) from 4 weeks of age. Ad libitum food consumption was 
monitored for 6 days. Progression of arthritis was assessed with a non-automated “cat-walk” 
walking gait test, which measured the distance between the central pads of two alternating 
10 
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hind footprints (Parvathy et al., 2013). All animal experiments were approved by The Roslin 
Institute’s Animal Users Committee and the animals were maintained in accordance with UK 
Home Office guidelines for the care and use of laboratory animals.  
 
Glucose and Insulin tolerance tests  
Juvenile and adult (6 and 16 week old respectively)  male mice were fasted for 4 hours and 
administered 2 mg of D-glucose (Sigma, Poole, UK) per g of body weight by gavage. 16 
week old male mice were fasted for 4 hours and administered 0.5 (control diet) or 0.75 (HFD) 
mU of insulin (Actrapid, NovoNordisk, Bagsvaerd, Denmark) per g of body weight, while 6 
week old male mice were administered 0.375 mU of insulin per g of body weight 
intraperitoneally (ip). At 0, 15, 30, 60 and 120 minutes intervals after administration blood 
glucose was measured with an Accu-Chek® Aviva glucose meter (Roche Diagnostics Ltd., 
Lewes, UK) and insulin was measured by ELISA (ChrystalChem, Chicago, IL, USA). 
Animals were subsequently sacrificed at 7 and 18 weeks of age respectively to allow for 
recovery from the tests. Tissues including pancreas, liver, quadratus femoris, soleus muscle 
and tibiae as well as brown, subcutaneous, mesenteric and gonadal fat pads were collected for 
histological assessment and gene expression analysis.  
 
Primary osteoblast cell culture  
Primary osteoblasts (pOBs) were isolated the calvariae of 3-5 day-old wild-type (WT) and 
Enpp1-/- mice as previously described (Huesa et al., 2010; Staines et al., 2013). Cells were 
seeded at a density of 2.5x104/cm2 in multi-well plates, in growth medium consisting of α-
MEM (Invitrogen, Paisley, UK) supplemented with 10% FBS (Invitrogen) and 1% 
gentamicin (Invitrogen). Cells were maintained in 95% air/5% CO2 at 37°C. 
 
Cell signaling immunoblotting 
Following confluency, pOBs were cultured for 24 hours in serum free medium containing 
0.1% bovine serum albumin (BSA). Cells were then either lyzed immediately or stimulated 
with insulin (10 nM; Sigma) or IGF-I (10 nM; Sigma) for 10 minutes before lysis.  Cells were 
lysed in RIPA buffer (Invitrogen) containing “phosphatase inhibitor cocktail 2” (Sigma) and 
“complete” protease inhibitor cocktail (Roche) according to manufacturers’ instructions. 
Immunoblotting with specific antibodies against phospho-Aktser473, total Akt, phospho-
GSK3βser9, total GSK3β phospho-Erk 1/2thr202/tyr204 and total Erk1/2 (Cell Signaling, Boston, 
MA, USA). Immunoblotting was conducted as previously described (Zhu et al., 2011; Zhu et 
11 
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al., 2013) and visualized using the enhanced chemi-luminescence (ECL) Western Blotting 
Detection System (GE Healthcare, Chalfont St Giles, UK). 
 
RNA extraction and qPCR 
Bone and fat tissues were extracted using Qiazol (Qiagen, Valencia, CA, USA) following 
standard protocol procedures. All other tissues and cell cultures were extracted with the 
RNeasy Qiagen kit following manufacturer’s instructions (Qiagen).  RNA was quantified and 
reverse transcribed as previously described (Mackenzie et al., 2011; Macrae  et al., 2009). All 
genes were analyzed with the SYBR green detection method (Roche) using the Stratagene 
Mx3000P real-time QPCR system (Agilent Technologies, Santa Clara, CA, USA). All gene 
expression data were normalized against Atp5B (Primer Design, Southampton, UK; sequence 
not disclosed) in osteoblasts, LRP10 in adipose tissue and Gapdh (Primer Design; sequence 
not disclosed) in all other tissues. The control values were expressed as 1 to indicate a precise 
fold change value for each gene of interest. All primer sequences were obtained from the 
Harvard primer bank database (http://pga.mgh.harvard.edu/primerbank/index.html, see 
supplementary material Table S1).   
 
Tissue histology and cell immunofluorescence  
Dissected tissues were fixed in 4% paraformaldehyde (PFA) or 10% phosphate buffered 
formalin (pH 7.4) and embedded in paraffin wax. 5 µm sections were stained with 
haematoxylin and eosin (H&E). Fresh tissues for lipid staining were collected immediately 
after euthanasia, snap frozen in precooled isopentane and stored at -80°C for less than 1 
month. Cryostat sections (10µm) were stained routinely for lipid with Oil Red O. Cells were 
plated onto glass cover slips, fixed in 4% PFA and permeabilized with 0.1% Triton in PBS 
prior to insulin receptor immunofluorescent staining following standard protocols (Huesa et 
al., 2010).  
 
Measurement of islet number and size  
Serial sections were cut through each pancreas at 100µm intervals, stained with H&E and 
scanned with a Nikon CoolScan V (Nikon, Surrey, UK). The total area of a stained pancreas 
section was measured along with the number and size of the islets in that section using 
ImageJ software (Wayne Rasband, National Institute of Health, USA). At least five randomly 
selected serial sections were examined per pancreas and three mice were analyzed for each 
diet/genotype group.  
12 
 
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
Ac
ce
pt
ed
 m
an
us
cr
ip
t
Micro-computed tomography (µCt) and mechanical testing of tibiae  
Tibiae were dissected and immediately frozen in PBS at -20°C pending analysis. High 
resolution scans with an isotropic voxel size of 5 µm were acquired with a micro-computed 
tomography system (µCT, 60 kV, 0.5 mm aluminium filter, 0.6 ° rotation, Skyscan 1172, 
Brukker microCT, Kontich, Belgium). Scans were reconstructed using NRecon software 
(Brukker microCT). For each bone, a 1000 µm section of the metaphysis was taken for 
analysis of trabecular bone, using the base of the growth plate as a standard reference point. 
A further 1500 µm below the base of the metaphysis section a 400 µm section of the mid-
diaphysis was scanned for analysis of cortical structure. Data was analyzed with CtAn 
software (Brukker microCT). Cortical porosity was measured in the 2D slice by slice 
analysis. Binarized objects were identified containing fully enclosed spaces, and porosity was 
calculated as the area of those spaces as a percent of the total area of binarized objects. It 
should be noted that for this study, total porosity is a measurement of all of the space within 
the cortical bone not filled by mineral e.g. a blood vessel canal, a large osteocyte lacuna or a 
crack. Mechanical testing of the cortical bone was assessed by 3 point bending analysis using 
a Zwick materials testing machine (Zwick A.G., Ulm, Germany) with a 50 N loading cell, 
where the span was set at 5.5 mm and the cross-head speed was set at 1mm/min. Data was 
analyzed as previously described (Huesa et al., 2011).  
 
Serum measurements  
Immediately following euthanasia, blood was obtained from non-fasted 6 and 12 week old 
male mice and serum samples prepared. Total, carboxylated (GLA), undercarboxylated 
(GLU13-OCN) and uncarboxylated (GLU) osteocalcin was measured as previously described 
(Ferron et al., 2010), as well as markers of bone formation (P1NP; IDS, Boldon, UK) and 
resorption (Ctx; IDS).  
 
Statistics  
Standard comparisons between WT and Enpp1-/- mice were analyzed by unpaired Student t-
test. Comparisons between genotype and diet were analyzed with two-way ANOVA. Time 
course experiments were analyzed with a repeated measures two-way ANOVA. Analysis was 
carried out using SigmaStat 12.0 (Systat Software Inc, London, UK). 
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Figure legends 
 
Figure 1. Enpp1-/- mice significant muscle reduction but not significant changes in fat 
mass. A) Body weight (g) growth curves for Enpp1-/- and WT mice (n=6). Enpp1-/- mice 
show reduced B) Quadratus femoris  and C) Soleus muscle weight relative to total body 
weight (mg/g), compared with WT controls  (n=6).  D) Walking gait stride length of Enpp1-/- 
and WT mice (n=4). E) Subcutaneous, messenteric, gonadal and brown fat pad weight 
relative to total body weight (mg/g) compared to WT controls (n=6). Relative expression of 
WAT markers and Insr in F) subcutaneous and G) gonadal fat pad.  Mice were reared under 
control dietary conditions and were 18 weeks of age at the time of dissection. Results are 
presented as mean ± SEM * P<0.05, ** P<0.01, *** P<0.001. 
 
Figure 2. Enpp1-/- mice exhibit insulin sensitization. A) Glucose tolerance test (GTT). B) 
Glucose stimulated insulin secretion (GSIS).  C) Insulin tolerance test (ITT) represented as 
percentage (%) of basal glucose. D) Metabolic tests analyzed as area under the curve. Mice 
were reared under control dietary conditions to 16 weeks of age. Results are presented as 
mean ± SEM (n=8) *P<0.05. 
 
Figure 3. Enpp1-/- mice show pronounced obesity-resistance in response to a chronic 
high fat diet challenge. Enpp1-/- and WT mice were reared on a high fat diet from 4 weeks of 
age.  A) Body weight (g) growth curves (n=16). B) Body weight (g) at 18 weeks of age (n=8).  
C) Walking gait stride length in WT and Enpp1-/- mice (n=4).  D) WAT weight analysis in 
ratio to total body weight (mg/g) (n=8). E) Maximum gonadal fat cell diameter (n=4). F) BAT 
weight analysis in ratio to total body weight (n=8). Gene expression of WAT and BAT 
markers and Insr in G) subcutaneous and H) gonadal fat pad.  I) Histological oil red O 
staining of lipid deposits in cryosections of the liver. Mice were analyzed at 18 weeks of age 
after 14 weeks under high fat dietary conditions. Results are presented as mean ± SEM 
*P<0.05, ** P<0.01, *** P<0.001, NS: non-significant. 
 
Figure 4. Enpp1-/- mice show improved insulin tolerance in response to a chronic high 
fat diet challenge. A) Glucose tolerance test (GTT), B) Glucose stimulated insulin secretion 
(GSIS) and C) Insulin tolerance test (ITT)  represented as percentage (%) of basal glucose. 
Mice were reared under high fat dietary conditions and were 16 weeks of age. Results are 
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presented as mean ± SEM (n=7) *P<0.05. D)  Metabolic tests analyzed as area under the 
curve. E) Number of islets.  F) Size of islets. Results are presented as mean ± SEM *P<0.05. 
 
Figure 5. Metabolic effects in Enpp1-/- mice are independent of bone insulin signaling 
but associated with altered osteocalcin carboxylation status. A) Immunofluorescent 
staining of the insulin receptor on the surface of wild type and Enpp1-/- neonatal calvarial 
primary osteoblast cultures. B) Relative mRNA expression levels of Insr in calvarial 
osteoblast cultures (n=6). C) Representative immunoblots demonstrating the effects of insulin 
(INS; 10 nM) and IGF-1 (10 nM) on the phosphorylation of Akt, Glycogen synthase kinase-3 
beta (GSK-3β) and Erk1/2 in calvarial osteoblasts cultures (n≥3). Measurement of serum D) 
total osteocalcin, E) carboxylated osteocalcin, F) undercarboxylated osteocalcin, G) 
uncarboxylated osteocalcin, H) bone formation marker P1NP and I) bone resorption marker 
CTX-I in 6 and 12 week old mice. Results are presented as mean ± SEM (n=6) *P<0.05. 
 
Figure 6. High fat diet induces a deterioration of trabecular bone architecture. 
Representative images of trabecular bone from 18 week old mice tibiae. A) WT control diet. 
B) Enpp1-/- control diet. C) WT high fat diet. D) Enpp1-/- high fat diet. E) Bone formation 
marker P1NP and F) bone resorption marker CTX-I in 6 and 12 week old mice. Results are 
presented as mean ± SEM (n=6) *P<0.05, *** P<0.001. 
 
Figure 7. Schematic representation of the effects of NPP1 on bone mineralization, 
obesity and glucose intolerance. NPP1 hydrolyses ATP to generate pyrophosphate (PPi), 
which is a key inhibitor of mineralization. Global deletion of Enpp1 results in decreased PPi 
levels, leading to ectopic calcification of blood vessels and cartilage. However, in lone bones, 
Enpp1 ablation leads to insufficient PPi substrate for TNAP to generate Pi for normal mineral 
formation. On the other hand, decreased PPi may reduce the ratio of OPG to RANKL, 
resulting in increased bone resorption by osteoclasts (Ribeiro et al., 2014). The acidic pH 
(4.5) in resorption lacunae decarboxylates osteocalcin (GLA-OCN) stored in the bone 
extracellular matrix to generate undercarboxylated active osteocalcin (GLU13-OCN), which 
stimulates insulin secretion by the β-cells of the pancreatic islets and promotes insulin 
sensitivity (Ferron and Lacombe, 2014). Increased insulin binds to the insulin receptor in 
osteoblasts and inhibits the expression of OPG, driving osteoclastic bone resorption and the 
further release of GLU13-OCN. Increased insulin secretion protects high fat diet induced 
obesity and glucose intolerance, and impacts on insulin sensitive tissues, such as muscle and 
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adipose. Additionally, GLU13-OCN may directly stimulate energy consumption in skeletal 
muscle and adipose tissue and may decrease lipid accumulation in the liver (Rosen and 
Motyl, 2010).  
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Translational Impact:  
 
Clinical issue: 
More than half a billion individuals worldwide suffer from obesity and its associated 
metabolic disease, such as type 2 diabetes. The emergence of bone as an endocrine regulator 
leads to revaluate the role of bone mineralization factors in the development of metabolic 
disease. Despite the recognized importance of Ectonucleotide 
pyrophosphatase/phosphodiesterase-1 (NPP1) in the regulation of bone mineralization, its 
contribution to obesity and type 2 diabetes remains less clear.   
 
Results: 
This research investigated the association of the metabolic phenotype and impaired bone 
metabolism in mice lacking the NPP1 gene (Enpp1-/- mice). The authors provide new 
evidence that Enpp1-/- mice showed a pronounced resistance to obesity and insulin resistance 
in response to chronic high fat feeding. Furthermore, the authors show that Enpp1-/- mice had 
increased levels of the insulin sensitising bone-derived hormone osteocalcin, although insulin 
signaling remains unchanged within osteoblasts. 
 
Implications and future directions: 
These findings shed more light on the important role of NPP1 in the development of obesity and 
type 2 diabetes and provide information on the mechanism by which this protein regulates insulin 
sensitivity. A fuller understanding of the pathways of NPP1 may inform the development of 
novel therapeutic strategies for treating insulin resistance. 
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 Parameter Control diet High fat diet 
Tr
ab
ec
ul
ar
 b
on
e 
  WT (n=6) Enpp1
-/-
 (n=6) WT (n=8) Enpp1
-/-
 (n=6) 
Percentage bone 
volume 
13.05 ± 4.388
b
 7.70 ± 2.101
b
 9.10 ± 3.119 5.36 ± 2.556 
Trabecular 
thickness (µm) 
50.8 ± 7.5 56.5 ± 6.1
b
 47.6 ± 3.30 47.6 ± 4.7 
Trabecular 
separation  (µm) 
214.1 ± 56.2 280.1 ± 50.1 247.5 ± 60.31 289.4 ± 80.9 
Trabecular 
number  (µm
-1
) 
0.00266 ± 0.00102 0.00137 ±0.00039
a
 0.00196 ± 0.0007778 0.00115 ± 0.00060
a
 
Trabecular pattern 
factor 
0.0255 ± 0.0075 0.0338 ± 0.00597
a,b
 0.0319 ± 0.004003 0.0419 ± 0.0066
a,b
 
Structure model 
index 
2.19 ± 0.56 2.74 ± 0.27
a,b
 2.38 ± 0.279 2.77 ± 0.34 
Degree of 
anisotropy 
2.44 ± 0.29
b
 2.51 ± 0.15
b
 2.20 ± 0.201 2.24 ± 0.40 
C
or
tic
al
 b
on
e 
Bone Mineral 
Density (g/cm
3
) 
1.29 ± 0.02
b
 1.31 ± 0.04 1.34 ± 0.02 1.32 ± 0.02 
Cortical thickness 
(µm) 
176.03 ± 15.49 175.61 ± 6.33
b
 181.35 ± 6.64 157.01 ± 13.00
a,b
 
Cortical porosity 
(%) 
2.14 ± 0.61 1.94 ± 0.44 2.08 ± 0.51 1.99 ± 0.29 
Maximum 
Stiffness (N/mm) 
54.77 ± 6.06 49.09 ± 3.30
a
 49.09 ± 3.83 48.66 ± 4.13 
Work to failure 
(N·mm) 
3.09 ± 1.12 2.26 ± 0.41 2.26 ± 0.44 2.33 ± 0.75 
Work to fracture 
(N·mm) 
9.21 ± 2.44
b
 7.60 ± 1.58
 a,b
 7.60 ± 1.46 4.99 ± 0.10
a,b,c
 
Work post-failure 
(N·mm) 
5.92 ± 1.80
 b
 5.29 ± 1.43
 a,b
 5.29 ± 1.38 2.62 ± 0.72
a,b,c
 
 
Table 1: Chronic high fat diet challenge induces an enhanced deterioration of 
trabecular bone architecture and exacerbates the disrupted bone mineralization 
phenotype of Enpp1-/- mice. Trabecular bone parameters were measured by µCt on 18 week 
old male tibiae. Results are presented as mean ± SD. Significant differences (P<0.05) a same 
diet vs WT, b same genotype vs high fat diet. Cortical bone parameters were measured by 
µCt on 18 week old male tibiae. The same bones were then tested for biomechanical 
properties by 3 point bending. Results are presented as mean ± SD. Significant differences 
(P<0.05) a same diet vs WT, b same genotype vs high fat diet, c vs different genotype and 
different diet. 
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